Teva Pharmaceutical Industries (TEVA) Assets Average (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Assets Average for 18 consecutive years, with $39.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 1.72% year-over-year to $39.9 billion; the trailing twelve-month figure through Jun 2026 stood at $39.9 billion (up 1.72% YoY), and the FY2025 full-year result was $40.0 billion, down 3.3% from the prior year.
• Assets Average slipped to $39.9 billion in Q2 2026 per TEVA's latest filing, from $40.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $47.4 billion in Q1 2022 and bottomed at $38.9 billion in Q1 2025.
• Historically, Assets Average has averaged $42.3 billion across 5 years, with a median of $42.3 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Assets Average fell 9.87% in 2025, then increased 3.92% in 2026.
• Over 5 years, Assets Average stood at $44.1 billion in 2022, then fell by 3.05% to $42.8 billion in 2023, then retreated by 5.25% to $40.5 billion in 2024, then dropped by 0.59% to $40.3 billion in 2025, then slipped by 0.88% to $39.9 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $39.9 billion, $40.4 billion, and $40.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.